Ruxolitinib Combined with Gemcitabine against Cholangiocarcinoma Growth via the JAK2/STAT1/3/ALDH1A3 Pathway.
Chung SY, Hung YP, Pan YR, Chang YC, Wu CE, Hsu DS, Chang PM, Lu ML, Huang CF, Su Y, Hsiao M, Yeh CN, Chen MH.
Chung SY, et al. Among authors: chang pm, chang yc.
Biomedicines. 2021 Jul 24;9(8):885. doi: 10.3390/biomedicines9080885.
Biomedicines. 2021.
PMID: 34440089
Free PMC article.